TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2059815

Group type: EXPERIMENTAL
Intervention: 40 mg tamoxifen daily and optimal surgery
Number of subjects: 381

Group type: COMPARATOR
Intervention: tamoxifen alone
Number of subjects: 381
Study: 6735044

Group type: EXPERIMENTAL
Intervention: Gelox (shielding antacid) after 500 mg of AAS
Number of subjects: 12

Group type: COMPARATOR
Intervention: AAS alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AAS + Gelox
Number of subjects: 12
Study: 30696977

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D) 50,000 IU weekly for 3 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 29499584

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27354258

Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Number of subjects: 500

Group type: COMPARATOR
Intervention: qHPV vaccine
Number of subjects: 500
Study: 25205201

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg twice daily plus amoxicillin 1 g thrice daily for 14 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Rabeprazole 10 mg twice daily plus amoxicillin 1 g thrice daily for 14 days
Number of subjects: 120
Study: 22798540

Group type: EXPERIMENTAL
Intervention: Intervention participants (n=92) received assistance from trained kidney transplant recipients who provided tailored information and support in completing transplant process steps.
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control participants (n=75) continued to receive usual care without additional support.
Number of subjects: 167
Study: 20699744

Group type: EXPERIMENTAL
Intervention: rFVIIa
Number of subjects: 2050

Group type: COMPARATOR
Intervention: Control (no rFVIIa)
Number of subjects: 2050
Study: 18171966

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty with navigation
Number of subjects: 320

Group type: COMPARATOR
Intervention: Total knee arthroplasty without navigation
Number of subjects: 320
Study: 15830980

Group type: EXPERIMENTAL
Intervention: Nucleoplasty (Coblation)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: CAM (Coblation‐Assisted Microdiscectomy)
Number of subjects: 64
Study: 12455715

Group type: EXPERIMENTAL
Intervention: ABPM 1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ABPM 3
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ABPM 1, ABPM 2, ABPM 3
Number of subjects: 30
Study: 10515673

Group type: EXPERIMENTAL
Intervention: HRT with progestin for 10 days during 12 week cycles of estrogen (17beta‐estradiol 2 mg per day, reduced to 1 mg during last 6 days)
Number of subjects: 240

Group type: COMPARATOR
Intervention: HRT with progestin for 10 days during monthly cycles of estrogen (17beta‐estradiol 2 mg per day, reduced to 1 mg during last 6 days)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Long cycle HRT
Number of subjects: 240
Study: 7640054

Group type: EXPERIMENTAL
Intervention: Continuous infusion of ifosfamide (9 g/m2 over 72 h)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Bolus administration of ifosfamide (3 g/m2 every 24 h for 3 days)
Number of subjects: 17
Study: 1904568

Group type: EXPERIMENTAL
Intervention: 0.2 mg transdermal E2 patches for 2 weeks, followed by 0.1 mg patches for 4 weeks (immediate ERT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.2 mg transdermal E2 patches for 2 weeks, followed by 0.1 mg patches for 4 weeks (delayed ERT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.2 mg transdermal E2 patches
Number of subjects: 24
Study: 7028704

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31400356

Group type: EXPERIMENTAL
Intervention: MICA-A4 allele
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: MICA*012:01 allele
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: MICA-A5 allele
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Homozygote MICA*012:01/012:01
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: MICB*008 allele
Number of subjects: 124
Study: 29055056

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/d
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 90
Study: 26695758

Group type: EXPERIMENTAL
Intervention: Natesto™ Testosterone Nasal Gel (11 mg b.i.d. or 11 mg t.i.d.)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Natesto™ Testosterone Nasal Gel (titration arm)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Natesto™ Testosterone Nasal Gel (fixed-dose arm)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Natesto™ Testosterone Nasal Gel
Number of subjects: 306
Study: 23474648

Group type: EXPERIMENTAL
Intervention: High-protein/calorie parenteral nutrition (HPC-PN)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (standard parenteral nutrition)
Number of subjects: 115
Study: 23168752

Group type: EXPERIMENTAL
Intervention: Long-acting reversible contraceptive (LARC) methods (IUDs and implants) provided at no cost
Number of subjects: 9256

Group type: EXPERIMENTAL
Intervention: CHOICE cohort receiving no-cost contraception
Number of subjects: 9256
Study: 20217117

Group type: EXPERIMENTAL
Intervention: E45 (90 min of exercise at 45% VO(2)peak)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: E65 (60 min of exercise at 65% VO(2)peak)
Number of subjects: 18

Group type: COMPARATOR
Intervention: C (sedentary control trial)
Number of subjects: 18
Study: 18029463

Group type: EXPERIMENTAL
Intervention: Recombinant human TNF-alpha (700 ng/m(2).h(1)) for 4 hours
Number of subjects: 10
Study: 16624589

Group type: EXPERIMENTAL
Intervention: EEG-fMRI
Number of subjects: 46
Study: 12358116

Group type: EXPERIMENTAL
Intervention: Geriatric rehabilitation in a geriatric ward
Number of subjects: 243

Group type: COMPARATOR
Intervention: Standard care in local hospital wards
Number of subjects: 243
Study: 10230190

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Behavior modification (BMOD)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 16
Study: 8807354

Group type: EXPERIMENTAL
Intervention: Mood and food cues (individualized high-risk/favorite foods)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Mood cues
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-risk foods presentation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cue presentation
Number of subjects: 15
Study: 1684704

Group type: EXPERIMENTAL
Intervention: Applied tension (AT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tension-only (T)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Exposure in vivo (E)
Number of subjects: 30
Study: 6310832

Group type: EXPERIMENTAL
Intervention: Azathioprine (Aza) and prednisone
Number of subjects: 122

Group type: COMPARATOR
Intervention: Cyclosporine and prednisone
Number of subjects: 122

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Aza
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Liver transplant group
Number of subjects: 122

Group type: COMPARATOR
Intervention: Cyclosporine patients
Number of subjects: 122
Study: 30925181

Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention
Number of subjects: 2329

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 2329
Study: 30389343

Group type: EXPERIMENTAL
Intervention: 0.1% cyclosporin A cationic emulsion (CsA CE)
Number of subjects: 62
Study: 28805670

Group type: EXPERIMENTAL
Intervention: Salacia Chinensis (300 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Salacia Chinensis (500 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Salacia Chinensis (300 mg) or (500 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 25623753

Group type: EXPERIMENTAL
Intervention: Subcutaneous delivery of trastuzumab via Single Injectable Device (SID)
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Subcutaneous delivery of trastuzumab via hand-held syringe (HHS)
Number of subjects: 467

Group type: COMPARATOR
Intervention: Intravenous delivery of trastuzumab
Number of subjects: 467
Study: 23926746

Group type: EXPERIMENTAL
Intervention: Roth 801 sealer mixed with a 10:1 powder/liquid ratio
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Roth 801 sealer mixed with a 7.5:1 powder/liquid ratio
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (8 teeth)
Number of subjects: 152
Study: 21406054

Group type: EXPERIMENTAL
Intervention: Various antiretroviral drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older and lesser used drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recently approved drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compounds under investigation
Number of subjects: 0
Study: 18418309

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 0
Study: 17012641

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) enhanced exercise program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no VR)
Number of subjects: 20
Study: 14582600

Group type: EXPERIMENTAL
Intervention: Sexual and STD/AIDS prevention program
Number of subjects: 536

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 536
Study: 11062273

Group type: EXPERIMENTAL
Intervention: Lubeluzole
Number of subjects: 1786

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1786
Study: 8940782

Group type: EXPERIMENTAL
Intervention: Pediatric probe
Number of subjects: 39

Group type: COMPARATOR
Intervention: Adult probe
Number of subjects: 39
Study: 8253699

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 3819

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3819
Study: 4003573

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (0.45 M)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Isotonic saline (0.15 M)
Number of subjects: 7
Study: 31195890

Group type: EXPERIMENTAL
Intervention: MTBI group
Number of subjects: 378

Group type: COMPARATOR
Intervention: Trauma controls
Number of subjects: 378

Group type: COMPARATOR
Intervention: Community controls
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Predictors of acute HAIH
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Predictors of persistent HAIH
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Patients with HAIH during the first 3 months post-injury
Number of subjects: 378
Study: 30019352

Group type: EXPERIMENTAL
Intervention: WHO‐5
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: BDI‐II
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: WHO‐5 and BDI‐II
Number of subjects: 699

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 699
Study: 26712182

Group type: EXPERIMENTAL
Intervention: Simultaneous aortic root and vein graft cold blood cardioplegia and continuous controlled warm blood perfusion through vein grafts during proximal ends anastomosis.
Number of subjects: 434

Group type: COMPARATOR
Intervention: Routine aortic root antegrade cardioplegia with no warm blood perfusion during proximal anastomosis of vein grafts.
Number of subjects: 434
Study: 25891543

Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg daily at 10 a.m.)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo (n=2) or no treatment (n=1)
Number of subjects: 3
Study: 23134886

Group type: EXPERIMENTAL
Intervention: Cerebral palsy (CP)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Typically developing children (TDC)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Marginally ambulant and nonambulant children with CP
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nonambulant children with CP
Number of subjects: 32
Study: 20180938

Group type: EXPERIMENTAL
Intervention: New Cooperative Medical Scheme (NCMS) reimbursement
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Cost control measures and other medical financial assistance (MFA)
Number of subjects: 881
Study: 18284461

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (HF patients with OSA, LVEF <45%, apnoea/hypopnoea index <10/h, n = 7)
Number of subjects: 19
Study: 15868252

Group type: EXPERIMENTAL
Intervention: Topical GTN (5 ml, 1 mg/ml)
Number of subjects: 104
Study: 11883772

Group type: EXPERIMENTAL
Intervention: Nucleus 22 Double Array (basal array)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nucleus 22 Double Array (both arrays)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nucleus 22 Double Array (apical array)
Number of subjects: 6
Study: 10401947

Group type: EXPERIMENTAL
Intervention: Chiron M865 lactate analyzer
Number of subjects: 17

Group type: COMPARATOR
Intervention: YSI mode 2300 lactate/glucose analyzer
Number of subjects: 17

Group type: COMPARATOR
Intervention: Hitachi 911 lactate/glucose/electrolyte/enzyme analyzer
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Chiron M865
Number of subjects: 17
Study: 7726425

Group type: EXPERIMENTAL
Intervention: Lidocaine 45 mg and epinephrine 15 micrograms (Group 5)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (Group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lidocaine 45 mg (Group 2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lidocaine 45 mg and epinephrine 5 micrograms (Group 3)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lidocaine 45 mg and epinephrine 10 micrograms (Group 4)
Number of subjects: 50
Study: 2029201

Group type: EXPERIMENTAL
Intervention: Long-term administration group (L) receiving Cyclophosphamide (CPA) at a total dose of 25 g/m2 over 18 months
Number of subjects: 308

Group type: COMPARATOR
Intervention: Short-term administration group (S) receiving Cyclophosphamide (CPA) at a total dose of 6 g/m2 over 6 months
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Long-term administration group (L)
Number of subjects: 308
Study: 117442

Group type: EXPERIMENTAL
Intervention: Pre-operative parenteral nutrition over a 7-10 day period
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 74
Study: 29420227

Group type: EXPERIMENTAL
Intervention: Azithromycin 7.5 mg/kg, 5 days/week for 4 weeks and 3 days/week for another 4 weeks with metronidazole 20 mg/kg/day for 8 weeks (group 1)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Metronidazole alone for 8 weeks (group 2)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Open-label azithromycin for failures in group 2
Number of subjects: 73
Study: 28194668

Group type: EXPERIMENTAL
Intervention: Raw rhubarb solution (250 cases drank a raw rhubarb soak solution per 3 hours until defecation after ERCP)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Water (control group, 250 cases drank water after ERCP)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Raw rhubarb solution
Number of subjects: 500

Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 500
Study: 25528692

Group type: EXPERIMENTAL
Intervention: Pictorial serving size recommendation on large pack
Number of subjects: 730

Group type: COMPARATOR
Intervention: Non-pictorial serving size recommendation
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Serving size recommendation (pictorial) in lab experiment
Number of subjects: 730

Group type: COMPARATOR
Intervention: No serving size recommendation in lab experiment
Number of subjects: 730
Study: 23499064

Group type: EXPERIMENTAL
Intervention: DEX implant 0.7 mg
Number of subjects: 329

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 329
Study: 17215530

Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg twice daily)
Number of subjects: 903

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 903
Study: 14764781

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone application (Virormone, 5 mg) for 8 or 12 hours
Number of subjects: 8
Study: 10833890

Group type: EXPERIMENTAL
Intervention: Moxonidine 40 mg alone in the morning
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Moxonidine 40 mg in combination with melatonin 3 mg overnight
Number of subjects: 50
Study: 9752921

Group type: EXPERIMENTAL
Intervention: Aspiration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspiration and injection of steroid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspiration (control group)
Number of subjects: 0
Study: 8411611

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg in the morning
Number of subjects: 43

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice a day
Number of subjects: 43

Group type: COMPARATOR
Intervention: Ranitidine (crossover to Omeprazole)
Number of subjects: 43
Study: 3085212

Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin, 12.5 mg/kg body weight, administered orally 30-240 min before surgery
Number of subjects: 33
Study: 30199744

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 10
Study: 28651550

Group type: EXPERIMENTAL
Intervention: C3 (2 mg/mL) applied four times daily for 2 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vehicle (water) applied to upper eyelids
Number of subjects: 30
Study: 27487640

Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rectal acetaminophen
Number of subjects: 120

Group type: COMPARATOR
Intervention: IV placebo
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo suppository
Number of subjects: 120
Study: 23572477

Group type: EXPERIMENTAL
Intervention: Healthy Eating and Exercise Lifestyle Program (HEELP)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 147
Study: 21819308

Group type: EXPERIMENTAL
Intervention: Cords at room temperature (CR)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cords stored on ice (CI)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Syringes at room temperature (SR)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Syringes stored on ice (SI)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study: 18805887

Group type: EXPERIMENTAL
Intervention: Continuous work pattern (three periods of 40 continuous minutes for each task)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Discontinuous work pattern (40 min tasks divided into four periods of 4, 8, 12 and 16 min)
Number of subjects: 24
Study: 17259696

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 600 mg/day for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no ALA treatment)
Number of subjects: 50
Study: 15175628

Group type: EXPERIMENTAL
Intervention: Intervention group (arranging follow-up appointments from the hospital)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Control group (no arrangement of follow-up appointments)
Number of subjects: 328
Study: 11756055

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Low-fat, complex carbohydrate diet (LF-CC)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Low-fat, simple carbohydrate diet (LF-SC)
Number of subjects: 46
Study: 9803986

Group type: EXPERIMENTAL
Intervention: Methotrexate (oral or intramuscular doses weekly)
Number of subjects: 62
Study: 7659386

Group type: EXPERIMENTAL
Intervention: Jet nebulizer (Respirgard II) with 2 ml volume fill (R2)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ultrasonic nebulizer (Ultraneb 99) with 4 ml volume fill (U4)
Number of subjects: 5
Study: 2473364

Group type: EXPERIMENTAL
Intervention: CHOP‐B
Number of subjects: 60

Group type: COMPARATOR
Intervention: CEOP‐B
Number of subjects: 60
Study: 937876

Group type: EXPERIMENTAL
Intervention: Tutored physicians
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control physicians (untutored)
Number of subjects: 0
Study: 31847915

Group type: EXPERIMENTAL
Intervention: Pulsed Laser Group (n=26) treated with 3 J/cm2
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pulsed Ultrasound Group (n=24) treated with 1 W/cm2 at 3 MHz
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Continuous Ultrasound Group (n=26) treated with 1 W/cm2 at 1 MHz
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control Group (n=24)
Number of subjects: 100
Study: 28940709

Group type: EXPERIMENTAL
Intervention: Encode protocol
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional protocol
Number of subjects: 44
Study: 26037798

Group type: EXPERIMENTAL
Intervention: Cisplatin and gemcitabine (CisGem) chemotherapy
Number of subjects: 462
Study: 23569146

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) for 12 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard medical therapy alone (non‐CRT group)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Controls (n = 20)
Number of subjects: 27
Study: 21320331

Group type: EXPERIMENTAL
Intervention: Clinic-based intensive lifestyle counseling alone (n = 80)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Clinic-based intensive lifestyle counseling combined with community health worker support (n = 80)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual primary care (n = 40)
Number of subjects: 200
Study: 19165639

Group type: EXPERIMENTAL
Intervention: Physical training (three brisk walks and 1-2 aerobic exercises/week for one year)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control (normal sedentary life)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Physical training and Control
Number of subjects: 112
Study: 17093157

Group type: EXPERIMENTAL
Intervention: Capillary blood sampling with glucose as the reference food
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Capillary blood sampling with white bread as the reference food
Number of subjects: 12

Group type: COMPARATOR
Intervention: Venous blood sampling
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Two tests of glucose solution as the reference
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Testing white bread as the reference 1, 2, or 3 times
Number of subjects: 12
Study: 15286687

Group type: COMPARATOR
Intervention: Cyclosporin A (CsA) alone
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) and Cyclosporin A (CsA) combination
Number of subjects: 34
Study: 11331446

Group type: EXPERIMENTAL
Intervention: Ion-implanted CVAD
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard CVAD
Number of subjects: 106